Pharmacogenomics in neurology: Current state and future steps
Identifieur interne : 000193 ( Main/Exploration ); précédent : 000192; suivant : 000194Pharmacogenomics in neurology: Current state and future steps
Auteurs : Andrew Chan [Allemagne, Espagne] ; Munir Pirmohamed [Royaume-Uni] ; Manuel Comabella [Espagne]Source :
- Annals of Neurology [ 0364-5134 ] ; 2011-11.
Abstract
In neurology, as in any other clinical specialty, there is a need to develop treatment strategies that allow stratification of therapies to optimize efficacy and minimize toxicity. Pharmacogenomics is one such method for therapy optimization: it aims to elucidate the relationship between human genome sequence variation and differential drug responses. Approaches have focused on candidate approaches investigating absorption‐, distribution‐, metabolism, and elimination (ADME)‐related genes (pharmacokinetic pathways), and potential drug targets (pharmacodynamic pathways). To date, however, only few genetic variants have been incorporated into clinical algorithms. Unfortunately, a large number of studies have thrown up contradictory results due to a number of deficiencies, including small sample sizes, inadequate phenotyping, and genotyping strategies. Thus, there still exists an urgent need to establish biomarkers that could help to select for patients with an optimal benefit to risk relationship. Here we review recent advances, and limitations, in pharmacogenomics for agents used in neuroimmunology, neurodegenerative diseases, ischemic stroke, epilepsy, and primary headaches. Further work is still required in all of these areas, which really needs to progress on several fronts, including better standardized phenotyping, appropriate sample sizes through multicenter collaborations and judicious use of new technological advances such as genome‐wide approaches, next generation sequencing and systems biology. In time, this is likely to lead to improvements in the benefit‐harm balance of neurological therapies, cost efficiency, and identification of new drugs. Ann Neurol 2011
Url:
DOI: 10.1002/ana.22502
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pharmacogenomics in neurology: Current state and future steps</title><author><name sortKey="Chan, Andrew" sort="Chan, Andrew" uniqKey="Chan A" first="Andrew" last="Chan">Andrew Chan</name></author><author><name sortKey="Pirmohamed, Munir" sort="Pirmohamed, Munir" uniqKey="Pirmohamed M" first="Munir" last="Pirmohamed">Munir Pirmohamed</name></author><author><name sortKey="Comabella, Manuel" sort="Comabella, Manuel" uniqKey="Comabella M" first="Manuel" last="Comabella">Manuel Comabella</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:50AE765BC60B8141A6DD3058F5AAF2AABD28C481</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/ana.22502</idno><idno type="url">https://api.istex.fr/document/50AE765BC60B8141A6DD3058F5AAF2AABD28C481/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002669</idno><idno type="wicri:Area/Main/Curation">002329</idno><idno type="wicri:Area/Main/Exploration">000193</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pharmacogenomics in neurology: Current state and future steps</title><author><name sortKey="Chan, Andrew" sort="Chan, Andrew" uniqKey="Chan A" first="Andrew" last="Chan">Andrew Chan</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, St. Josef‐Hospital, Ruhr‐University Bochum</wicri:regionArea><wicri:noRegion>Ruhr‐University Bochum</wicri:noRegion><wicri:noRegion>Ruhr‐University Bochum</wicri:noRegion></affiliation><affiliation wicri:level="2"><country xml:lang="fr">Espagne</country><wicri:regionArea>Andrew Chan, Department of Neurology, St. Josef‐Hospital, Ruhr‐University, Gudrunstr. 56, D‐44791 Bochum, GermanyManuel Comabella, Centre d'Esclerosi Múltiple de Catalunya, CEM‐Cat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron (HUVH), Passeig de la Vall d'Hebron, 119‐129, E‐08035 Barcelona</wicri:regionArea><placeName><region nuts="2" type="communauté">Catalogne</region></placeName></affiliation></author><author><name sortKey="Pirmohamed, Munir" sort="Pirmohamed, Munir" uniqKey="Pirmohamed M" first="Munir" last="Pirmohamed">Munir Pirmohamed</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Wolfson Centre for Personalised Medicine, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool</wicri:regionArea><wicri:noRegion>Liverpool</wicri:noRegion></affiliation></author><author><name sortKey="Comabella, Manuel" sort="Comabella, Manuel" uniqKey="Comabella M" first="Manuel" last="Comabella">Manuel Comabella</name><affiliation wicri:level="3"><country xml:lang="fr">Espagne</country><wicri:regionArea>Centre d'Esclerosi Múltiple de Catalunya, CEM‐Cat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron (HUVH), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">Espagne</country><wicri:regionArea>Andrew Chan, Department of Neurology, St. Josef‐Hospital, Ruhr‐University, Gudrunstr. 56, D‐44791 Bochum, GermanyManuel Comabella, Centre d'Esclerosi Múltiple de Catalunya, CEM‐Cat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron (HUVH), Passeig de la Vall d'Hebron, 119‐129, E‐08035 Barcelona</wicri:regionArea><placeName><region nuts="2" type="communauté">Catalogne</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-11">2011-11</date><biblScope unit="volume">70</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="684">684</biblScope><biblScope unit="page" to="697">697</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">50AE765BC60B8141A6DD3058F5AAF2AABD28C481</idno><idno type="DOI">10.1002/ana.22502</idno><idno type="ArticleID">ANA22502</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In neurology, as in any other clinical specialty, there is a need to develop treatment strategies that allow stratification of therapies to optimize efficacy and minimize toxicity. Pharmacogenomics is one such method for therapy optimization: it aims to elucidate the relationship between human genome sequence variation and differential drug responses. Approaches have focused on candidate approaches investigating absorption‐, distribution‐, metabolism, and elimination (ADME)‐related genes (pharmacokinetic pathways), and potential drug targets (pharmacodynamic pathways). To date, however, only few genetic variants have been incorporated into clinical algorithms. Unfortunately, a large number of studies have thrown up contradictory results due to a number of deficiencies, including small sample sizes, inadequate phenotyping, and genotyping strategies. Thus, there still exists an urgent need to establish biomarkers that could help to select for patients with an optimal benefit to risk relationship. Here we review recent advances, and limitations, in pharmacogenomics for agents used in neuroimmunology, neurodegenerative diseases, ischemic stroke, epilepsy, and primary headaches. Further work is still required in all of these areas, which really needs to progress on several fronts, including better standardized phenotyping, appropriate sample sizes through multicenter collaborations and judicious use of new technological advances such as genome‐wide approaches, next generation sequencing and systems biology. In time, this is likely to lead to improvements in the benefit‐harm balance of neurological therapies, cost efficiency, and identification of new drugs. Ann Neurol 2011</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Espagne</li><li>Royaume-Uni</li></country><region><li>Catalogne</li></region><settlement><li>Barcelone</li></settlement></list><tree><country name="Allemagne"><noRegion><name sortKey="Chan, Andrew" sort="Chan, Andrew" uniqKey="Chan A" first="Andrew" last="Chan">Andrew Chan</name></noRegion></country><country name="Espagne"><region name="Catalogne"><name sortKey="Chan, Andrew" sort="Chan, Andrew" uniqKey="Chan A" first="Andrew" last="Chan">Andrew Chan</name></region><name sortKey="Comabella, Manuel" sort="Comabella, Manuel" uniqKey="Comabella M" first="Manuel" last="Comabella">Manuel Comabella</name><name sortKey="Comabella, Manuel" sort="Comabella, Manuel" uniqKey="Comabella M" first="Manuel" last="Comabella">Manuel Comabella</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Pirmohamed, Munir" sort="Pirmohamed, Munir" uniqKey="Pirmohamed M" first="Munir" last="Pirmohamed">Munir Pirmohamed</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000193 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000193 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:50AE765BC60B8141A6DD3058F5AAF2AABD28C481
|texte= Pharmacogenomics in neurology: Current state and future steps
}}
| This area was generated with Dilib version V0.6.23. |  |